Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.78−0.08 (-0.81%)
Close on Nov 17, 2026Market cap $1.37BP/E –Yield –
Intellia Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Intellia Therapeutics's price to sales ratio was 26.8× on Nov 11, 2026, against 18.1× a year earlier. Over the last 5 years it ranged from 12.5× to 328.1×, with a median of 61.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 26.8× | +8.8 |
| 2025 | Dec 31, 2025 | 18.1× | −22.9 |
| 2024 | Jan 31, 2024 | 41.0× | −11.5 |
| 2023 | Dec 29, 2023 | 52.5× | +0.5 |
| 2022 | Dec 30, 2022 | 52.0× | −276.1 |
| 2021 | Dec 31, 2021 | 328.1× | +276.8 |
| 2020 | Dec 31, 2020 | 51.3× | +33.4 |
| 2019 | Dec 31, 2019 | 17.9× | −2.4 |
| 2018 | Dec 31, 2018 | 20.3× | – |
See a number that looks wrong?